Promising New Platforms and Targets in the Management of Gastroesophageal Cancers
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-518912 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Jeesun Yoon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National Universi…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit nennt 88 Literaturangaben.
Abstract (Originalsprache)
Gastric and gastroesophageal junction cancers remain a major global cause of cancer-related mortality. Despite incremental advances in surgery and systemic therapy, durable survival gains have been limited, underscoring persistent unmet medical needs. However, the treatment paradigm has undergone a rapid transformation, driven by the integration of immunotherapy in curative-intent systemic treatment and the expansion of biomarker-guided systemic therapies. In the perioperative setting, immune checkpoint inhibitors combined with optimized cytotoxic chemotherapy have demonstrated encouraging efficacy, with recent phase III trials contributing to the establishment of combination of immunotherapy and chemotherapy as an emerging therapeutic platform. In advanced disease, precision oncology frameworks continue to expand beyond traditional biomarkers. Established targets such as human epidermal growth factor receptor 2 are now complemented by newly validated markers including claudin18.2, whereas additional actionable alterations—such as MET and TROP2—are actively under clinical investigation. These developments are redefining treatment algorithms and introducing new sequencing considerations, particularly in the context of tumor heterogeneity and biomarker coexpression. Concurrent advances in molecular diagnostics and next-generation sequencing are also facilitating the comprehensive identification of therapeutically relevant alterations. This review outlines the evolving therapeutic landscape of gastric and gastroesophageal junction cancers, spanning perioperative immunotherapy, newly validated molecular targets, and next-generation drug development platforms. By integrating biomarker-driven strategies with innovative modalities, such as antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor-T-cell therapy, and vaccines, we highlight how precision therapeutics are reshaping treatment paradigms across resectable and advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
- Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA.
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom.
ORCID-Profile: Jeesun Yoon, Do-Youn Oh
Zitieren
APA
Yoon, J., Chen, C. Y., Watson, R., Smyth, E., Wainberg, Z., & Oh, D. Y. (2026). Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-518912
Vancouver
Yoon J, Chen CY, Watson R, Smyth E, Wainberg Z, Oh DY. Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-518912
BibTeX
@article{Yoon2026,
author = {Yoon, Jeesun and Chen, Caroline Y and Watson, Robert and Smyth, Elizabeth and Wainberg, Zev and Oh, Do-Youn},
title = {Promising New Platforms and Targets in the Management of Gastroesophageal Cancers},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-518912}
}
EUVIMED